What
A prescription blood test that can help detect cancers based on the presence of Circulating Tumour Cells (CTC’s). The test has a 88.2% sensitivity in detection of cancers across all stages and types. Furthermore, it has a 93.1% accuracy in determining the tissue or organ of origin in positive cases. Thus, even early stage cancers are reliably detected. Furthermore, Trucheck specificity is 96.3% in asymptomatic individuals and 95% in individuals with benign tumours.

For Whom
Asymptomatic adult males and females with no previous cancer diagnosis and above the age of 35 years old.

How
Blood samples are evaluated the presence of circulating tumour cells (CTC’s) which may be further analysed to determine the organ or tissue of origin. The blood test appointment takes 20-30 minutes and you will receive your results within 2 weeks.

Why
The Trucheck Intelli blood test is a convenient, accurate and safe way to detect cancer at the earliest stage.

What

Trucheck FemmeSafe is a prescription only blood-based screening test based on the presence of Circulating Tumour Cells (CTCs). It is validated for the early detection of the following adenocarcinomas: 

• Breast 
• Ovarian 
• Uterus 
• Squamous cell carcinoma of the Cervix

CTC-based screening tests performed has shown a sensitivity of 88/24% for detection and localization of solid organ malignancies, a specificity of 96.5% was observed in asymptomatic individuals and a specificity of 95% was observed in individuals with benign tumours.

For whom

Asymptomatic females above 40 years old with no previous cancer diagnosis.

How

Trucheck FemmeSafe test analyses circulating tumour cells (CTCs) in peripheral blood samples. It detects adenocarcinomas in the breast, ovary, uterus and squamous cell cervix. If CTCs are present, this indicates a higher risk of the presence of women’s cancers. When CTCs are not detected, the patients can consider annual testing while continuing with their participation in standard cancer screening programmes. 

Why

Cancers of the breast, ovary, cervix, and uterus account for approximately 3.6 million diagnosed cases and 1.3 million deaths in women annually, worldwide (Globocan, 2020). Early detection of these cancers results in more effective treatments and improved survival prospects. Screening is currently available for breast and cervical cancers but is unavailable for ovarian and uterine cancers. Trucheck FemmeSafe addresses this current void in asymptomatic women by facilitating accurate early detection of these cancers.

What 

Hereditary cancer is defined as cancer caused by an inherited genetic variant in a cancer susceptibility gene. Identifying a genetic fault means you have an increased risk of developing cancer, but it doesn’t mean that you have or will be diagnosed with cancer in the future.

Faecal Immunochemical Testing (FIT)

What

The FIT test analyses stool samples to identify possible signs of bowel cancer, such as blood in the stool that you might not be able to see. It has a sensitivity of 88% and a specificity of 91% for colorectal cancer.

Patients with a positive FIT result can be referred for further investigation. The earlier bowel cancer is found, the more effective treatments will be and the more curable the cancer. 

For whom

The FIT test is available for both males and females over 18 years of age.

How

• Gently scrape the outer surfaces of the stool, until the grooved end of the probe is evenly covered.
• Insert the probe into the tube and twist until you hear it click shut.
• Secure the sample into the sample tube mailer and place into original shipping box.
• Place the box into the prepaid envelope and seal.
• Post via Royal Mail Postal box.
• It takes approximately 5 working days for analysis once the sample has been received at the laboratory.

Why

Bowel cancer is the fourth most common cancer in the UK and the second biggest cancer killer. Nearly 43,000 individuals are diagnosed with bowel cancer every year in the UK (Bowel Cancer UK, July 2023). The FIT test is currently used as a bowel cancer screening method for over 50’s by the NHS, however, more than 2600 people under 50 are diagnosed each year in the UK (Bowel Cancer UK, Autumn 2022). These individuals will be missed by the screening programme, therefore diagnosis won’t occur until they develop symptoms and go through the NHS diagnostic pathway. This test reaches those people to ensure that if bowel cancer is present, it is diagnosed at the earliest possible stage when treatment is most successful.  

The blood test and Whole-Body MRI scan are two separate parts of the programme and can be chosen independently.

Why

Depending on the risk assessment of your medical history, family history, and blood test results, we may advise you to have the MRI scan.

What

MRI stands for Magnetic Resonance Imaging. An MRI machine is a large magnet which uses strong magnetic fields to ‘see inside’ your body. It is completely pain-free and requires no injections. The scan extends from the top of your head to the middle of your thighs and takes approximately 1 hour to perform. You will be able to listen to music with special headphones for the duration of the scan. 

A full safety questionnaire will be undertaken prior to your attendance at the scan clinic to exclude any possible contra-indications for the session.

Is the process safe?

Yes. MRI scans have been used since the 1980s and are proven safe. Unlike other medical imaging procedures such as CT (CAT scan) and X-ray, MRIs do not expose you to harmful radiation.

• To triage symptomatic individuals who have been advised an invasive tissue biopsy to check for malignancy
• Patients where an invasive biopsy has been inconclusive or inconsistent with clinical observations
• Suspected metastatic relapse to rule out a new primary cancer.
• Every Individual who desires a “risk free biopsy”

What
Non-invasive diagnostic biopsy to substitute invasive tissue extraction.

Why
Invasive biopsies are risky, inconvenient, painful, and must be performed in a clinical setting. Trublood sample is a simple 25ml blood draw that can be collected from a patient’s house or office.

How
Circulating tumour cells are isolated from a patient’s blood sample and extensively analysed for diagnosis, prognosis, and theranostics.